Avastin (bevacizumab) indicated in mCRC, NSCLC, mBC, mRCC and advanced ovarian cancer in combination with chemotherapy. Information from Roche for healthcare professionals.

Educational webcast

Educational webcast

Prof Robert Burger discusses the incorporation of bevacizumab in the primary treatment of ovarian cancer and reviews the latest data from the phase III trial, GOG 0218

Educational webcast

Challenges in the treatment of mCRC

Prof Dirk Arnold
Germany
Controlling angiogenesis to control tumour growth

Avastin precisely targets VEGF to inhibit angiogenesis for continuous tumour control
Expert perspectives in mCRC

Safety and tolerability in mCRC

Prof Alfredo Falcone
Italy

Expert perspectives

Inhibiting angiogenesis

Prof Alberto Sobrero
Italy
Avastin MoA

Interactive modular MoA slide set with a detailed voiceover
Expert perspectives in ovarian cancer

Avastin in OC is exciting

Prof Eric Pujade Lauraine
France

<>

Resources
Webcasts
Patient Cases

Outcomes in potentially resectable patients
Discussion of treatment of mCRC patients with liver metastases, according to resectability status (Prof Thomas Gruenberger)
Bevacizumab plus IFN in mRCC
Latest clinical trial data on the efficacy of first-line Avastin plus IFN in mRCC (Dr Camillo Porta)
From tumour biology to biomarkers
An insight into the evolving role of biomarkers for anti-angiogenesis therapy in oncology (Dr Donald McDonald)

NSCLC patient case
A patient with centrally located adenocarcinoma of the lung (Dr Martin Reck)
mBC patient case
A patient with hormone receptor-positive aggressive breast cancer (Dr Sunil Verma)
CRC patient case
A patient with rectal adenocarcinoma and unresectable liver metastases (Prof Michel Ducreux)

Upcoming Conferences

EACR
,
Barcelona, Spain

7-10 July 2012
UICC-WCC
,
Montreal, Canada

27-30 August 2012
ESMO
,
Vienna, Austria

28 September 2012 - 02 October 2012

More upcoming conferences

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.